33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Association between post-treatment (tx) alpha-fetoprotein (AFP) reduction and outcomes in real-world (rw) US patients (pts) with advanced HCC (aHCC)
    Meeting Abstract

    Wang, X.; Magee, K.; Gossai, A.; Parrinello, C. M.; Miksad, R. A.; Kim, R. D.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Trifluridine/tipiracil outcomes in third- or later lines versus placebo in metastatic gastric cancer treatment: An exploratory subgroup analyses from the TAGS study
    Meeting Abstract

    Tabernero, J.; Shitara, K.; Zaanan, A.; Doi, T.; Lorenzen, S.; Van Cutsem, E.; Fornaro, L.; Catenacci, D. V. T.; Fougeray, R.; Vera, S. R. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)
    Meeting Abstract

    Strickler, J. H.; Ng, K.; Cercek, A.; Fountzilas, C.; Sanchez, F. A.; Hubbard, J. M.; Wu, C.; Siena, S.; Tabernero, J.; Van Cutsem, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
    Meeting Abstract

    Tabernero, J.; Bang, Y. J.; Van Cutsem, E.; Fuchs, C. S.; Janjigian, Y. Y.; Bhagia, P.; Li, K.; Adelberg, D. E.; Qin, S. K.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma - Trial in Progress
    Meeting Abstract

    Strickler, J. H.; Nakamura, Y.; Yoshino, T.; Catenacci, D. V. T.; Janjigian, Y. Y.; Barzi, A.; Bekaii-Saab, T. S.; Lenz, H. J.; Lee, J.; Van Cutsem, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer
    Meeting Abstract

    Shiu, K. K.; Andre, T.; Kim, T. W.; Jensen, B. V.; Jensen, L. H.; Punt, C. J. A.; Smith, D. M.; Garcia-Carbonero, R.; Benavides, M.; Gibbs, P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Exposure-response (E-R) efficacy and safety (E-S) analyses of tremelimumab as monotherapy or in combination with durvalumab in patients (pts) with unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Song, X.; Kelley, R. K.; Khan, A.; Standifer, N.; Krishna, R.; Liu, L.; Wang, K.; Green, M.; McCoon, P.; Negro, A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Strickler, J. H.; Ou, F. S.; Bekaii-Saab, T. S.; Parseghian, C. M.; Cercek, A.; Ng, K.; Sanchez, F. A.; Bruggeman, S.; Larson, J. J.; Finley, G. G.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC)
    Meeting Abstract

    Schwartz, L. H.; Kindler, H. L.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC)
    Meeting Abstract

    Sangro, B.; Harding, J. J.; Johnson, M.; Palmer, D. H.; Edeline, J.; Abou-Alfa, G. K.; Cheng, A. L.; Decaens, T.; El-Khoueiry, A. B.; Finn, R. S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save